आपके बैज 52W रेंज $81–$158 91% of range विश्लेषक रेटिंग HOLD 25 analysts मूल्य लक्ष्य $129 P/E 46.7 ROE 3.3% शुद्ध लाभ मार्जिन 8.5%

RVTY स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

03
मूल्य $151.53
मार्केट कैप (MRQ) $16.91B
P/E 46.7
EPS $2.07
राजस्व $2.86B
लाभांश प्रतिफल 0.30%
ROE 3.3%
D/E ऋण/इक्विटी (MRQ) 0.4
52W रेंज $81–$158

RVTY स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

04
सीमा
बार

बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।

स्टॉक विभाजन 4
एक्स-डेट स्प्लिट प्रकार
4 जून 2001 2-for-1 फॉरवर्ड
11 मई 1992 2-for-1 फॉरवर्ड
2 फ़रवरी 1982 2-for-1 फॉरवर्ड
4 फ़रवरी 1980 2-for-1 फॉरवर्ड

Revvity, Inc. Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

05 · wikidata

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.

Over its history, PerkinElmer has been split in two twice. In 1999, PerkinElmer merged with EG&G, with the ongoing Analytical Instruments Division of Perkin-Elmer keeping that name, while the life sciences division of the company became the separate PE Corporation. In 2022, a split of PerkinElmer resulted in one part, comprising applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but kept the PerkinElmer name. The other part, comprising life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.

History

Founding

Richard Perkin was attending the Pratt Institute in Brooklyn to study chemical engineering, but left after a year to try his hand on Wall Street. Still interested in the sciences, he gave public lectures on various topics. Charles Elmer ran a firm that supplied court reporters and was nearing retirement when he attended one of Perkin's lectures on astronomy being held at the Brooklyn Institute of Arts and Sciences.

The two struck up a friendship over their shared interest in astronomy, and eventually came up with the idea of starting a firm to produce precision optics. Perkin raised US$15,000 from his relatives, while Elmer added US$5,000, and the firm was initially set up as a partnership on 19 April 1937. Initially, they worked from a small office in Manhattan, but soon opened a production facility in Jersey City. They incorporated the growing firm on 13 December 1939. A further move to Glenbrook in Connecticut in 1941 was quickly followed by another move to Norwalk, Connecticut, where the company remained until 2000. The opening of World War II led to significant expansion as the company produced optics for range finders, bombsights, and reconnaissance systems. This work led to the U.S. Navy awarding them the first "E" for Excellence award in 1942.

Perkin-Elmer retained a strong presence in the military field through the 1960s and at the same time was significantly involved with OAO-3 a 36-inch Ultra Violet Space Telescope and Skylab. They contributed to the Apollo program by development of a CO2 sensor that was, however, supplanted by a Coleman Instruments product. PE at the Norwalk plant also conducted one of the first researches into computer-digital enhancement of scanned images, contracted for application to the Corona spy satellite, film imagery. They were a primary supplier of the optical systems used in many reconnaissance platforms, first in aircraft and high-altitude balloons, and then in reconnaissance satellites. A significant advance was 1955's Transverse Panoramic Camera, which took images on 12 by 14 ft (3.7 by 4.3 m) wide frames that provided single-frame images from horizon to horizon from an aircraft flying at 40,000 ft altitude. Such systems remained a major part of the company's income, capped by the installation of laser retroreflectors on the Moon as part of the Apollo 11 mission.

Elmer died at age 83 in 1954, and the company began trading shares over the counter. The company was listed on the New York Stock Exchange on 13 December 1960. Perkin remained as president and CEO until June 1961, when Robert Lewis, previously of Argus Camera and Sylvania Electric Products, took over these roles. Perkin remained the chairman of the board until his death in 1969.

Semiconductor manufacturing

In 1967, the U.S. Air Force asked Perkin-Elmer to produce an all-optical "masking" system for semiconductor fabrication. Previous systems used a pattern, the "mask", which was pressed onto the surface of the silicon wafer as part of the photolithography process. Small bits of dirt or photoresist would stick the mask and ruin the patterning for subsequent chips, and it was not uncommon for the vast majority of the chips from a given wafer to malfunction. The Air Force, which by the late 1960s was highly reliant on integrated circuits, desired a more reliable system.

Perkin-Elmer responded with the Microprojector, which was essentially a large photocopier system. The mask was placed in a holder and never touched the surface of the chip. Instead, the image was projected onto the surface. Making this work required a complex 16-element lens system that focussed a narrow range of wavelengths of light onto the mask. The remainder of the light from the 1,000 watt mercury-vapor lamp was filtered out. PE also developed a micro-densitometer in 1967 that scanned micro-chips for quality control

Harold Hemstreet was convinced that the concept could be simplified, and Abe Offner began the development of a system using mirrors instead of lenses, which did not suffer from the multispectral focussing problems of lenses. The result of this research was the Projection Scanning Aligner, or Micralign, which made chip making an assembly-line task and improved the number of working chips from perhaps 10% to 70% overnight. Chip prices plummeted as a result, with examples like the MOS 6502 selling for about US$20 while the previous generation of designs like the Motorola 6800 sold for around US$250.

The Micralign was so successful that Perkin-Elmer became the largest single vendor in the chip space in three years. In spite of this success, the company was largely a has-been by the 1980s due to their late response to the introduction of the stepping aligner, which allowed a single small mask to be stepped across the wafer, rather than requiring a single large mask covering the entire wafer. The company never regained their lead, and sold the division to The Silicon Valley Group.

Lab equipment

Perkin Elmer was a leading developer and supplier of lab analytic equipment from the 1950's. By the 1960's the Norwalk/Wilton, CT facilities were developing and producing a wide variety of instruments including multi-spectral spectrometers (IR, visible, UV), gas chromatographs, and atomic absorption spectrometers and Raman spectrometers. The plants housed integrated research, engineering, production (optical and electronic) and support facilities. In the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.

Computer Systems Division

Perkin-Elmer was involved in computer manufacture for a time. The Perkin-Elmer Computer Systems Division was formed through the purchase of Interdata, Inc., an independent computer manufacturer, in 1973–1974 for some US$63 million. This merger made Perkin-Elmer's annual sales rise to over US$200 million. This was also known as Perkin-Elmer's Data Systems Group. The 32-bit computers were very similar to an IBM System/370, but ran the OS/32MT operating system. In 1976, Perkin-Elmer acquired Wangco, a Los Angeles manufacturer of tape drives for $30 million in a stock swap.

The Computer Systems Division had a large presence in Monmouth County, New Jersey, with some 1,700 staff making it one of the county's largest private employers. Its plant in Oceanport had 800 employees alone. By the early-mid-1980s the computing group had sales of $259 million; while profitable, it tended to have reduced visibility within the computing industry due to being owned by a diversified parent.

The Wollongong Group provided the commercial version of the Unix port to the Interdata 7/32 hardware, known as Edition 7 Unix. The port was originally done by the University of Wollongong in New South Wales, Australia, and was the first UNIX port to hardware other than the Digital Equipment Corporation PDP family. By 1982, the Wollongong Group Edition 7 Unix and Programmer's Workbench (PWB) were available on models such as the Perkin-Elmer 3210 and 3240 minicomputers.

In 1985, the computing division of Perkin-Elmer was spun off as Concurrent Computer Corporation, with the goal of giving it and the parallel processing product a clearer identification within the computer industry. At first, the new company was a wholly owned subsidiary of Perkin-Elmer, but with the intentions of putting a minority ownership in the company up for a public stock sale. This was done one in February 1986, with Perkin-Elmer retaining an 82 percent stake in Concurrent. In 1988, there was a merger between Concurrent Computer Corporation and MASSCOMP; as part of the deal, Perkin-Elmer's share in Concurrent was bought out. At that point, Perkin-Elmer said they had culminated their multi-year process of exiting from computer market, allowing them to focus on their primary business segments.

1999

Modern PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly NYSE: EGG) of Wellesley, Massachusetts and Perkin-Elmer (formerly NYSE: PKN) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new board of directors. At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.

The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (NYSE: CRA) and PE Biosystems (formerly NYSE: PEB), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble. Perkin-Elmer purchased the Boston operations of NEN Life Sciences in 2001.

Recently

In 1992, the company merged with Applied Biosystems. In 1997 they merged with PerSeptive Biosystems. On July 14, 1999, the new analytical instruments maker PerkinElmer cut 350 jobs, or 12%, in its cost reduction reorganization. In 2006, PerkinElmer sold off the Fluid Sciences division for approximately US$400 million; the aim of the selloff was to increase the strategic focus on its higher-growth health sciences and photonic markets. Following on from the selloff, a number of small businesses were acquired, including Spectral Genomics, Improvision, Evotec-Technologies, Euroscreen, ViaCell, and Avalon Instruments. The brand "Evotec-Technologies" remains the property of Evotec, the former owner company. PerkinElmer had a license to use the brand until the end of year 2007.

PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired NTD Labs located on Long Island, New York. The laboratory specializes in prenatal screening during the first trimester of pregnancy. In 2007, it purchased ViaCell, Inc. for US$300 million, which included its offices in Boston and cord blood storage facility in Kentucky near Cincinnati. The company was renamed ViaCord.

In 2001 Perkin Elmer acquired Packard Bioscience Inc from its majority shareholder, Dick McKernen. This acquisition also came with Agincourt Technologies Inc and consolidated Perkin Elmer's position in laboratory robotics, in particular, liquid handling robots which were to prove essential for the high-throughput sequencing needed for the Human Genome Project.

In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, Pennsylvania specializing in screening newborns for various inborn errors of metabolism such as phenylketonuria, hypothyroidism, and sickle-cell disease. It renamed the laboratory PerkinElmer Genetics, Inc.

In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.

In September 2011, PerkinElmer bought Caliper Life Sciences for US$600 million.

In December 2014 PerkinElmer acquired Perten Instruments for US$266 million to expand in food testing.

In January 2016, PerkinElmer acquired Swedish firm Vanadis Diagnostics.

In February 2016 PerkinElmer acquired Delta Instruments.

In January 2017, the company announced it would acquire the Indian in vitro diagnostic company, Tulip Diagnostics. In May 2017, the company acquired Euroimmun Medical Laboratory Diagnostics for approximately US$1.3 billion.

In 2018, the company acquired Australian biotech company, RHS Ltd., Chinese manufacturer of analytical instruments, Shanghai Spectrum Instruments Co. Ltd., and France-based company Cisbio Bioassays, which specializes in diagnostics and drug discovery solutions.

In November 2020, PerkinElmer announced it would acquire Horizon Discovery Group for around US$383 million.

In March 2021, PerkinElmer announced that the company has completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). In May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. In June the company announced it would acquire SIRION Biotech, a specialist in viral vector gene delivery methods. In July the business announced it would acquire BioLegend for $5.25 billion.

Acquisition history

Programs

Hubble optics project

Perkin-Elmer's Danbury Optical System unit was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror began in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. Perkin-Elmer's own calculations and measurements revealed the primary mirror's surface discrepancies, but the company chose to withhold that data from NASA. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that revealed the miscalibration. Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, Corrective Optics Space Telescope Axial Replacement, was applied entirely to the secondary mirror and replaced existing instrumentation; the aberration of the primary mirror remained uncorrected.

The company agreed to pay US$15 million, essentially forgoing its fees in polishing the mirror, to avoid a threatened liability lawsuit under the False Claims Act by the Federal government. Hughes Aircraft, which acquired the Danbury Optical System unit one month after the launch of the telescope, paid US$10 million. The Justice Department asserted that the companies should have known about the flawed testing. Trade group Aerospace Industries Association protested when concerns were raised in the aerospace industry that aerospace companies might be held liable for failed equipment.

KH-9 Hexagon

Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

क्षेत्रHealthcare उद्योगLife Sciences Tools & Services कर्मचारी11000 देशUS

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

06
राजस्व$2.86B
2017-01-01 → 2025-12-28
EPS$2.07
2017-01-01 → 2025-12-28
फ्री कैश फ्लो$509M
2017-01-01 → 2025-12-28
शुद्ध मार्जिन8.5%
2017-01-01 → 2025-12-28
मूल्यांकन और अनुपात 07–12

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक 5Y रुझान RVTY 5Y औसत सहकर्मी माध्यिका निर्णय
P/E 46.75Y औसत ≈34.7 ≈34.7 46.0 अति मूल्यांकित
P/S 3.85Y औसत ≈5.1 ≈5.1 7.1 अल्पमूल्यित
P/B (MRQ) 2.35Y औसत ≈2.2 ≈2.2 6.8 अल्पमूल्यित
EV / EBITDA 17.35Y औसत ≈19.0 ≈19.0 25.4 अल्पमूल्यित
Price / FCF (मूल्य / FCF) 21.35Y औसत ≈291.5 ≈291.5 · ·
Price / Cash Flow (मूल्य / नकदी प्रवाह) 18.65Y औसत ≈46.4 ≈46.4 28.0 अल्पमूल्यित
EV / Revenue (EV / राजस्व) 4.65Y औसत ≈6.1 ≈6.1 · ·
EV / FCF 25.85Y औसत ≈341.5 ≈341.5 · ·
मूल्य / मूर्त पुस्तक (MRQ) 3.4 · · ·

सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।

मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय

लाभांश यील्ड, भुगतान अनुपात, लाभांश इतिहास, 5Y CAGR

13
लाभांश यील्ड0.30%
भुगतान अनुपात13.6%
वार्षिक भुगतान≈$0.28तिमाही भुगतान
5Y लाभांश CAGR≈0.00%प्रति शेयर, विभाजन-समायोजित
एक्स-डेटराशिमुद्रायील्ड
जुल 17, 2026$0.07USD≈0.25%
अप्र 17, 2026$0.07USD≈0.30%
जन 16, 2026$0.07USD≈0.25%
अक्ट 17, 2025$0.07USD≈0.30%
जुल 18, 2025$0.07USD≈0.30%
अप्र 17, 2025$0.07USD≈0.30%
जन 17, 2025$0.07USD≈0.24%
अक्ट 18, 2024$0.07USD≈0.23%
जुल 19, 2024$0.07USD≈0.26%
अप्र 18, 2024$0.07USD≈0.28%
जन 18, 2024$0.07USD≈0.26%
अक्ट 19, 2023$0.07USD≈0.28%
जुल 20, 2023$0.07USD≈0.22%
अप्र 20, 2023$0.07USD≈0.21%
जन 19, 2023$0.07USD≈0.21%
अक्ट 20, 2022$0.07USD≈0.22%
जुल 21, 2022$0.07USD≈0.19%
अप्र 21, 2022$0.07USD≈0.18%
जन 20, 2022$0.07USD≈0.16%
अक्ट 21, 2021$0.07USD≈0.16%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

14
औसत आश्चर्य 5.0%
अगली रिपोर्ट अक्ट 26, 2026
Periodरिपोर्टEPS ActualEPS अनुमानआश्चर्य
30 जून 2026 जुल 27, 2026 $1.41 $1.25 13.1%
31 मार्च 2026 $1.06 $1.04 2.3%
31 दिसमबर 2025 $1.70 $1.58 7.4%
30 सितमबर 2025 $1.18 $1.16 1.7%
30 जून 2025 $1.18 $1.16 1.5%
31 मार्च 2025 $1.01 $0.97 4.3%

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

15
आय विवरण 17
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Cost of Revenue ·······$1.44B$709M$665M$696M$708M
Gross Profit ···$1.99B$2.43B$2.11B$1.40B$1.34B$1.07B$1.01B$964M$1.00B
R&D Expense $216M$197M$217M$222M$200M$146M$189M$194M$139M$124M$113M$108M
SG&A Expense $992M$994M$1.02B$1.03B$975M$716M$815M$812M$626M$590M$587M$648M
Operating Income $357M$347M$301M$743M$1.26B$867M$362M$324M$296M$295M$251M$165M
Interest Expense ·····$50M$64M$67M$44M$42M$38M$36M
Interest Income $31M$73M$72M$4M$2M$1M$1M$1M$3M$702.0K$673.0K$667.0K
Other Non-op $-88M$-31M$-118M$-91M$-3M$-5M$-6M$-13M$43M$-15M$-5M$-6M
Pretax Income $268M$316M$183M$652M$1.20B$800M$237M$258M$297M$244M$209M$124M
Income Tax $28M$33M$3M$139M$314M$170M$9M$20M$140M$28M$20M$-6M
Net Income $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
EPS (Basic) $2.07$2.21$5.56$4.51$8.12$6.52$2.06$2.15$2.67$2.14$1.89$1.40
EPS (Diluted) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
Shares (Basic) 116,542,000122,756,000124,704,000126,155,000116,165,000111,514,000110,827,000110,561,000109,857,000109,478,000112,507,000112,593,000
Shares (Diluted) 116,595,000122,822,000124,812,000126,426,000116,674,000112,085,000111,501,000111,534,000110,859,000110,313,000113,315,000113,739,000
EBITDA $762M$775M$732M$1.17B$1.69B$1.23B$576M$504M$410M$383M$398M$327M
बैलेंस शीट 28
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Cash & Equivalents $920M$1.16B$913M$454M$603M$387M$192M$163M$202M$359M$238M$175M
Short-term Investments ·$0$690M$0········
Receivables $745M$632M$633M$613M$708M$1.16B$725M$633M$552M$426M$415M$471M
Inventory $379M$368M$428M$405M$426M$515M$357M$338M$352M$247M$259M$285M
Other Current Assets $196M$186M$337M$122M$148M$167M$100M$101M$94M$99M$64M$138M
Current Assets $2.24B$2.35B$3.00B$3.29B$2.44B$2.24B$1.37B$1.23B$1.20B$1.19B$1.03B$1.07B
PP&E (Net) $479M$482M$510M$483M$486M$368M$318M$319M$298M$145M$138M$176M
PP&E (Gross) $1.09B$982M$983M$857M$844M$818M$702M$680M$631M$428M$402M$493M
Accum. Depreciation $614M$500M$473M$374M$359M$450M$383M$362M$333M$282M$264M$317M
Goodwill $6.61B$6.46B$6.53B$6.48B$6.63B$2.64B$3.11B$2.95B$3.00B$2.25B$2.24B$2.24B
Intangibles $2.35B$2.64B$3.02B$3.38B$3.82B$1.37B$1.28B$1.20B$1.35B$420M$486M$490M
Other Non-current Assets $323M$288M$343M$311M$317M$333M$284M$270M$244M$205M$198M$107M
Total Assets $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Accounts Payable $185M$167M$204M$273M$325M$327M$236M$221M$222M$168M$141M$174M
Accrued Liabilities $557M$485M$524M$528M$679M$944M$503M$529M$501M$400M$382M$403M
Current Liabilities $1.33B$653M$1.45B$1.54B$1.21B$1.65B$763M$772M$951M$603M$561M$597M
Capital Leases $148M$152M$133M$170M$147M$188M$146M$0····
Deferred Tax ···········$30M
Other Non-current Liabilities $807M$771M$931M$1.11B$1.43B$775M$751M$742M$849M$460M$465M$443M
Total Liabilities $4.92B$4.73B$5.69B$6.75B$7.86B$4.22B$3.72B$3.39B$3.59B$2.12B$2.06B$2.09B
Long-term Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.99B$2.07B$1.89B$2.01B$1.05B$480M$1.05B
Total Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.61B$2.06B$1.88B$1.79B$1.05B$1.01B$1.05B
Common Stock $112M$121M$123M$126M$126M$112M$111M$111M$110M$110M$112M$112M
Retained Earnings $6.05B$5.85B$5.61B$4.95B$4.42B$3.51B$2.81B$2.60B$2.38B$2.12B$1.99B$1.81B
AOCI $-222M$-396M$-277M$-447M$-163M$-32M$-200M$-176M$-47M$-101M$-46M$25M
Stockholders' Equity $7.25B$7.67B$7.87B$7.38B$7.14B$3.74B$2.81B$2.58B$2.50B$2.15B$2.11B$2.04B
Liabilities + Equity $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Shares Outstanding 112,281,000120,646,0000126,300,000126,241,000112,090,000111,140,000110,361,000110,361,000109,617,000112,481,000112,481,000
नकदी प्रवाह 17
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
D&A $405M$428M$432M$427M$311M$202M$214M$181M$105M$100M$105M$110M
Stock-based Comp $23M$38M$41M$52M$30M$27M$32M$29M$25M$17M$17M$14M
Deferred Tax $-61M$-102M$-124M$-106M$-55M$-35M$-61M$-51M$29M$-5M$-10M$-34M
Amort. of Intangibles $336M$359M$365M$371M$257M$161M$164M$136M$74M$72M$77M$81M
Restructuring ·$18M$27M$14M$-14M$8M$29M$11M$13M$5M$14M$13M
Other Non-cash $-25M$-6M$-951M$-262M$126M$-82M$-48M$-85M$-163M$4M$-48M$26M
Operating Cash Flow $583M$628M$91M$680M$1.41B$892M$363M$311M$288M$351M$287M$282M
CapEx $74M$87M$81M$86M$86M$64M$76M$93M$39M$32M$28M$27M
Investing Cash Flow $-17M$776M$1.31B$-133M$-4.11B$-504M$-488M$-160M$-1.27B$-84M$-101M$-296M
Stock Repurchased $821M$370M$389M$81M$73M$7M$6M$57M$4M$152M$76M$66M
Net Stock Activity $-821M$-370M$-389M$-81M$-73M$-7M$-6M$-57M$-4M$-152M$-76M$-66M
Dividends Paid $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M
Financing Cash Flow $-858M$-1.13B$-947M$-662M$2.94B$-203M$-150M$-179M$782M$-115M$-107M$31M
Net Change in Cash $-243M$250M$444M$-149M$217M$211M$26M$-36M$-174M$138M$63M$2M
Taxes Paid $131M···········
Free Cash Flow $509M$542M$10M$594M$1.31B$815M$287M$218M$249M$319M$257M$253M
Levered FCF ·····$775M$226M$156M$226M$282M$224M$218M
लाभप्रदता 8
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Gross Margin ···60.1%·55.8%48.4%48.3%47.5%47.9%45.3%44.9%
Operating Margin 12.5%12.6%10.9%22.4%26.3%25.9%12.6%11.7%13.5%13.4%12.7%9.4%
Net Margin 8.5%9.8%25.2%17.2%18.6%19.2%7.9%8.6%13.0%11.1%9.4%7.0%
Pretax Margin 9.4%11.5%6.7%19.7%25.3%24.0%8.2%9.3%13.2%11.5%10.8%7.6%
EBITDA Margin 26.7%28.1%26.6%35.3%33.4%32.4%20.0%18.2%18.2%18.1%17.6%14.6%
ROA 2.0%2.1%5.0%3.9%8.2%10.0%3.6%3.9%5.6%5.5%5.1%3.9%
ROE 3.3%3.5%8.9%7.9%13.4%20.9%8.2%9.2%12.6%11.0%10.2%7.8%
ROIC 3.0%2.9%2.5%5.0%8.1%14.7%7.1%6.7%3.8%7.8%8.0%6.5%
तरलता और शोधन क्षमता 5
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Current Ratio 1.73.62.12.12.01.41.81.61.32.01.81.8
Quick Ratio 1.32.71.50.71.40.91.21.00.81.31.21.1
Debt / Equity 0.40.40.50.60.70.40.70.70.70.50.50.5
LT Debt / Equity 0.40.40.40.50.70.40.70.70.70.50.50.5
Interest Coverage ·····19.75.74.86.96.87.55.8
दक्षता 3
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.20.20.20.40.50.50.50.40.50.50.6
Inventory Turnover ·······4.22.42.62.82.9
Receivables Turnover 4.14.44.45.04.74.04.24.74.65.05.04.8
प्रति शेयर 6
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Book Value / Share $64.57$63.55$63.79$58.46$56.57$33.33$25.44$23.37$22.68$19.22$18.84$18.16
Revenue / Share $24.50$22.43$22.04$26.20$43.43$33.75$25.86$24.91$20.36$19.18$19.97$19.67
Cash Flow / Share $5.00$5.12$0.73$5.38$12.09$7.96$3.26$2.79$2.60$3.18$2.53$2.48
Cash / Share $8.19$9.64$7.40$3.60$4.90$3.59$1.73$1.47$1.83$3.21$2.12$1.55
Dividend / Share $0.28$0.28$0.28$0.28·$0.28$0.28$0.28$0.28$0.28$0.28$0.28
EPS (TTM) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
विकास दरें 10
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue YoY 3.7%0.16%-17.0%-13.5%1.2%·······
Revenue CAGR 3Y -4.8%-10.4%-10.1%·········
Revenue CAGR 5Y -5.5%···········
EPS YoY -5.9%-60.4%23.3%-44.3%24.5%·······
EPS CAGR 3Y -22.8%-35.2%-5.1%·········
EPS CAGR 5Y -20.4%···········
Net Income YoY -10.8%-61.0%21.8%-39.6%29.6%·······
Net Income CAGR 3Y -24.9%-34.1%-1.6%·········
Net Income CAGR 5Y -19.8%···········
Dividends Paid CAGR 5Y 1.0%···········
मूल्यांकन (TTM) 16
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Net Income TTM $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
Market Cap $10.86B$13.51B$13.49B$17.71B$25.38B$16.08B$10.73B$8.55B$8.07B$5.84B$6.00B$4.96B
Enterprise Value $13.16B$15.50B$15.79B$21.65B$29.74B$17.29B$12.61B$10.26B$9.66B$6.53B$6.78B$5.83B
P/E 46.750.919.731.224.922.147.636.327.724.628.631.7
P/S 3.84.94.95.36.64.33.73.13.62.82.92.2
P/B 1.51.81.72.43.64.33.83.33.22.72.82.4
P / Cash Flow 18.621.5147.826.118.018.029.527.528.016.720.917.6
P / FCF 21.324.91362.229.819.419.737.439.232.418.323.319.6
EV / EBITDA 17.320.021.618.517.614.121.920.323.617.017.017.8
EV / FCF 25.828.61594.136.422.721.243.947.138.720.526.323.1
EV / Revenue 4.65.65.76.57.84.64.43.74.33.13.22.6
Dividend Yield 0.30%0.26%0.26%0.20%0.13%0.19%0.29%0.36%0.38%0.53%0.53%0.64%
Earnings Yield 2.1%2.0%5.1%3.2%4.0%4.5%2.1%2.8%3.6%4.1%3.5%3.1%
Payout Ratio 13.6%12.7%5.0%6.2%3.4%4.3%13.7%13.0%10.5%13.2%14.9%20.0%
Annual Payout $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M

सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

16
मेट्रिक 2025-12-282024-12-292023-12-312023-01-012022-01-02
राजस्व $2.86B $2.76B $2.75B $3.31B $3.83B
सकल मार्जिन % · · · 60.1% ·
परिचालन मार्जिन % 12.5% 12.6% 10.9% 22.4% 26.3%
शुद्ध आय $241M $270M $693M $569M $943M
तनुकरणित EPS $2.07 $2.20 $5.55 $4.50 $8.08

संस्थागत मालिक (13F) 576 फाइलर्स · $11.1B कुल · तिथि अनुसार 30 सितमबर 2026

17

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

धारक 576
धारित मूल्य $11.1B
नई स्थितियाँ 101
बाहर निकली पोजीशन 53
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
101 (+19 पिछली तिमाही की तुलना में) 53 (-14 पिछली तिमाही की तुलना में) 195 (+16 पिछली तिमाही की तुलना में) 163 (+4 पिछली तिमाही की तुलना में) -8.8M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
VANGUARD GROUP INC $1273316785 13160897 11.42% शेयर
EdgePoint Investment Group Inc. $950658734 8544479 8.53% शेयर
BlackRock, Inc. $852070090 7658369 7.64% शेयर
VANGUARD CAPITAL MANAGEMENT LLC $812306256 7300973 7.29% शेयर
JANUS HENDERSON GROUP PLC $731386229 8348127 6.56% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $530760044 4770448 4.76% शेयर
STATE STREET CORP $483173141 4342739 4.33% शेयर
VICTORY CAPITAL MANAGEMENT INC $384362134 3454630 3.45% शेयर
DIMENSIONAL FUND ADVISORS LP $381477581 3428692 3.42% शेयर
GEODE CAPITAL MANAGEMENT, LLC $328197297 2955227 2.94% शेयर
MORGAN STANLEY $286475399 2574826 2.57% शेयर
Invesco Ltd. $269802164 2424970 2.42% शेयर
Allspring Global Investments Holdings, LLC $251393303 2227874 2.25% शेयर
NEUBERGER BERMAN GROUP LLC $208728363 1876041 1.87% शेयर
UBS Group AG $207440264 1864464 1.86% शेयर
Pictet Asset Management Holding SA $181501112 1631343 1.63% शेयर
CITADEL ADVISORS LLC $162143092 1457335 1.45% शेयर
RGM Capital, LLC $147000789 1519388 1.32% शेयर
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $120784746 1085608 1.08% शेयर
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. $120187725 1080242 1.08% शेयर
NORTHERN TRUST CORP $105092080 944563 0.94% शेयर
GOLDMAN SACHS GROUP INC $100173074 900351 0.90% शेयर
WELLINGTON MANAGEMENT GROUP LLP $96303874 865575 0.86% शेयर
NORGES BANK $96183046 864489 0.86% शेयर
PRIMECAP MANAGEMENT CO/CA/ $94921470 853150 0.85% शेयर
BANK OF AMERICA CORP /DE/ $87116298 782997 0.78% शेयर
Bank of New York Mellon Corp $78765533 707941 0.71% शेयर
VANGUARD FIDUCIARY TRUST CO $69620945 625750 0.62% शेयर
JANE STREET GROUP, LLC $64087317 576014 0.57% शेयर
JPMORGAN CHASE & CO $54177057 481955 0.49% शेयर
FMR LLC $51807384 465642 0.46% शेयर
SEI INVESTMENTS CO $48628856 437074 0.44% शेयर
Quantinno Capital Management LP $47076898 423125 0.42% शेयर
DEUTSCHE BANK AG\ $45437583 408391 0.41% शेयर
FEDERATED HERMES, INC. $43043267 386871 0.39% शेयर
Diamond Hill Capital Management, LLC (Investment Advisor) $42868033 385296 0.38% शेयर
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $41752209 476569 0.37% शेयर
MANUFACTURERS LIFE INSURANCE COMPANY, THE $41048042 368938 0.37% शेयर
Freestone Grove Partners LP $36716134 330003 0.33% शेयर
Legal & General Group Plc $31388230 282116 0.28% शेयर
CIBC Bancorp USA Inc. $29112955 261625 0.26% शेयर
Nuveen, LLC $27202014 244491 0.24% शेयर
California Public Employees Retirement System $27021271 242866 0.24% शेयर
BNP PARIBAS FINANCIAL MARKETS $25920242 232970 0.23% शेयर
WEDGE CAPITAL MANAGEMENT L L P/NC $25784587 294311 0.23% शेयर
Vanguard Global Advisers, LLC $25557201 229707 0.23% शेयर
Swiss National Bank $24955618 224300 0.22% शेयर
CIBC Private Wealth Group LLC $23946556 273207 0.21% शेयर
Artisan Partners Limited Partnership $22320536 200616 0.20% शेयर
Meridiem Capital Partners LP $21483638 193094 0.19% शेयर

सभी 576 संस्थागत मालिक दिखाएँ →

कार्यकर्ता और 5%+ मालिक 2 होल्डिंग्स

18

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
PERKINELMER, INC. 16 सितमबर 2011 · प्रारंभिक फाइलिंग M&A / बिक्री SEC
अघोषित रिपोर्टिंग व्यक्ति 23 जुलाई 2001 · प्रारंभिक फाइलिंग M&A / बिक्री SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

कंपनी के अंदरूनी सूत्र 46 इनसाइडर्स · 27 अधिकारी · 20 निदेशक

19
अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
Robert F Friel Chairman and CEO 13 फ़रवरी 2019 F 570662 0 0 $0
Maxwell Krakowiak Senior Vice President and Chief Financial Officer 21 सितमबर 2026 S 14781 0 1 $-235728
James M Mock Senior Vice President and Chief Financial Officer 24 जून 2022 S 27577 0 0 $0
Frank Anders Wilson Senior Vice President and Chief Financial Officer 5 मार्च 2018 M 61925 0 0 $0
Jeffrey D Capello SVP & CFO 29 जनवरी 2008 A 91428 0 0 $0
John Patrick Murphy Chief Operating Officer 1 अगस्त 2005 M 68589 0 0 $0
Anita Gonzales VP and CAO 1 अक्टूबर 2026 S 7117 0 3 $-29790
Tajinder Vohra Senior Vice President, Global Operations 16 सितमबर 2026 S 6635 0 2 $-1634152
Joel S Goldberg Senior Vice President, Administration, General Counsel and Secretary 14 अगस्त 2026 G 91494 0 4 $-1274357
Miriame Victor Senior Vice President, Chief Commercial Officer 24 फ़रवरी 2026 M 18122 0 1 $-180856
Daniel R Tereau Senior Vice President, Strategy and Business Development 5 फ़रवरी 2024 A 13246 0 0 $0
Andrew Okun Vice President, Chief Accounting Officer and Treasurer 13 अप्रैल 2023 M 4356 0 0 $0
Deborah A. Butters Senior Vice President, Chief Human Resources Officer 7 फ़रवरी 2020 F 12383 0 0 $0
James Corbett Executive Vice President and President, Discovery & Analytical Solutions 30 अप्रैल 2019 F 40531 0 0 $0
Jonathan P. Divincenzo Senior Vice President and President, Environmental Health 9 फ़रवरी 2016 A 23158 0 0 $0
John R Letcher Senior Vice President, Human Resources 5 जून 2015 D 26894 0 0 $0
Maurice H. Tenney Senior Vice President, Global Operations and Customer Logistics 7 नवमबर 2014 D 12241 0 0 $0
Daniel R Marshak SVP & CSO 26 सितमबर 2014 D 67743 0 0 $0
Kevin E Hrusovsky Senior Vice President, President Life Sciences and Technology 31 मई 2013 D 0 0 0 $0
John A Roush Senior Vice President 9 फ़रवरी 2010 A 120407 0 0 $0
Richard F Walsh SVP & CAO 26 जनवरी 2010 D 183491 0 0 $0
Gregory L Summe Exe. Chairman of the Board 27 फ़रवरी 2009 S 231724 0 0 $0
Michael Louis Battles VP & Chief Accounting Officer 3 फ़रवरी 2009 A 33750 0 0 $0
Katherine A Ohara SVP, Gen. Counsel, & Secretary 29 जनवरी 2008 A 65886 0 0 $0
Peter B Coggins Sr. Vice President 28 अक्टूबर 2005 M 87070 0 0 $0
Robert A Barrett Sr. Vice President 3 मार्च 2004 M 2333 0 0 $0
Terrance L Carlson Sr. VP & General Counsel 27 जनवरी 2004 J 2759 0 0 $0
Alexis P. Michas निदेशक 25 अगस्त 2026 G 6985 0 0 $0
Michelle Mcmurry-Heath निदेशक 7 मई 2026 A 6513 0 1 $-58356
Michael A Klobuchar निदेशक 7 मई 2026 A 7368 0 0 $0
Pascale Witz निदेशक 7 मई 2026 A 15985 0 0 $0
Samuel R. Chapin निदेशक 7 मई 2026 A 22676 0 0 $0
Michel Vounatsos निदेशक 7 मई 2026 A 13977 0 0 $0
Frank Witney निदेशक 7 मई 2026 A 23354 0 0 $0
Sophie V. Vandebroek निदेशक 7 मई 2026 A 7368 0 0 $0
Peter Barrett निदेशक 7 मई 2026 A 28293 0 0 $0
Sylvie Gregoire निदेशक 15 मई 2023 A 20482 0 0 $0
SULLIVAN PATRICK J निदेशक 30 अप्रैल 2019 A 30580 0 0 $0
Nicholas A Lopardo निदेशक 5 फ़रवरी 2019 S 39635 0 0 $0
Vicki L Sato निदेशक 9 फ़रवरी 2017 M 29970 0 0 $0
Kenton J Sicchitano निदेशक 24 अगस्त 2016 M 27971 0 0 $0
MULLEN JAMES C निदेशक 14 नवमबर 2014 M 45551 0 0 $0
Gabriel Schmergel निदेशक 16 फ़रवरी 2012 M 48012 0 0 $0
Robert G Tod निदेशक 14 फ़रवरी 2012 M 42824 0 0 $0
Tamara J Erickson निदेशक 14 फ़रवरी 2007 S 15352 0 0 $0
Prahlad R. Singh · 13 अगस्त 2026 G 59650 0 5 $-2557859

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

ईटीएफ स्वामित्व 96 ETFs द्वारा धारित

20

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
RSPH · Invesco Exchange-Traded Fund Trust 2.02% 115244 SH 1 अक्टूबर 2026 दैनिक
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.13% 6936 NS 31 जुलाई 2026 N-PORT
ALTL · Pacer Funds Trust 0.98% 8002 NS 31 जुलाई 2026 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 0.87% 53854 SH 1 अक्टूबर 2026 दैनिक
HIBL · Direxion Shares ETF Trust 0.66% 4421 NS 31 जुलाई 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0.50% 14749 NS 31 जुलाई 2026 N-PORT
DFSV · Dimensional ETF Trust 0.43% 313113 NS 31 जुलाई 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0.43% 39813 NS 31 जुलाई 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0.36% 14789 NS 31 जुलाई 2026 N-PORT
DFAT · Dimensional ETF Trust 0.35% 444437 NS 31 जुलाई 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0.34% 37032 SH 1 अक्टूबर 2026 दैनिक
BKMC · BNY Mellon ETF Trust 0.32% 18499 NS 31 जुलाई 2026 N-PORT
ESML · iShares Trust 0.29% 66388 SH 11 सितमबर 2026 दैनिक
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.27% 49018 NS 31 जुलाई 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0.26% 1624934 SH 19 अगस्त 2026 दैनिक
RSP · Invesco Exchange-Traded Fund Trust 0.25% 1580743 SH 1 अक्टूबर 2026 दैनिक
IYH · iShares Trust 0.22% 65502 SH 11 सितमबर 2026 दैनिक
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.21% 8343 NS 31 जुलाई 2026 N-PORT
SMMD · iShares Trust 0.19% 59552 SH 11 सितमबर 2026 दैनिक
BSCT · Invesco Exchange-Traded Self-Indexe… 0.18% 5732000 1 अक्टूबर 2026 दैनिक
FHLC · FIDELITY COVINGTON TRUST 0.18% 53129 NS 31 जुलाई 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.18% 335880 SH 19 अगस्त 2026 दैनिक
DFAS · Dimensional ETF Trust 0.18% 241849 NS 31 जुलाई 2026 N-PORT
ISCG · iShares Trust 0.18% 13989 SH 11 सितमबर 2026 दैनिक
IXJ · iShares Trust 0.17% 58518 SH 11 सितमबर 2026 दैनिक
REVS · Columbia ETF Trust I 0.17% 4910 NS 31 जुलाई 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0.15% 2559509 SH 19 अगस्त 2026 दैनिक
CURE · Direxion Shares ETF Trust 0.14% 2195 NS 31 जुलाई 2026 N-PORT
IWS · iShares Trust 0.13% 167213 SH 11 सितमबर 2026 दैनिक
WSML · iShares Trust 0.13% 7071 SH 11 सितमबर 2026 दैनिक
EQAL · Invesco Exchange-Traded Fund Trust … 0.12% 6239 SH 1 अक्टूबर 2026 दैनिक
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0.12% 8519 NS 31 जुलाई 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 0.11% 4047000 1 अक्टूबर 2026 दैनिक
RECS · Columbia ETF Trust I 0.11% 55761 NS 31 जुलाई 2026 N-PORT
PEXL · Pacer Funds Trust 0.10% 460 NS 31 जुलाई 2026 N-PORT
IWR · iShares Trust 0.10% 456822 SH 11 सितमबर 2026 दैनिक
PFIG · Invesco Exchange-Traded Fund Trust … 0.08% 113000 1 अक्टूबर 2026 दैनिक
XT · iShares Trust 0.08% 25072 SH 11 सितमबर 2026 दैनिक
XOEF · iShares Trust 0.08% 142 SH 11 सितमबर 2026 दैनिक
FNX · First Trust Exchange-Traded AlphaDE… 0.08% 9258 NS 31 जुलाई 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0.07% 4175 SH 1 अक्टूबर 2026 दैनिक
DFAC · Dimensional ETF Trust 0.06% 238422 NS 31 जुलाई 2026 N-PORT
DXUV · Dimensional ETF Trust 0.05% 2685 NS 31 जुलाई 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0.05% 33073 SH 1 अक्टूबर 2026 दैनिक
DFSU · Dimensional ETF Trust 0.05% 10422 NS 31 जुलाई 2026 N-PORT
DFUV · Dimensional ETF Trust 0.05% 65386 NS 31 जुलाई 2026 N-PORT
IVE · iShares Trust 0.05% 185121 SH 11 सितमबर 2026 दैनिक
IUSV · iShares Trust 0.04% 98188 SH 11 सितमबर 2026 दैनिक
VOOV · VANGUARD ADMIRAL FUNDS 0.04% 25806 SH 19 अगस्त 2026 दैनिक
DSI · iShares Trust 0.04% 17178 SH 11 सितमबर 2026 दैनिक
DCOR · Dimensional ETF Trust 0.04% 11339 NS 31 जुलाई 2026 N-PORT
CHRI · Global X Funds 0.04% 27 NS 31 जुलाई 2026 N-PORT
IWD · iShares Trust 0.04% 247738 SH 11 सितमबर 2026 दैनिक
QVML · Invesco Exchange-Traded Fund Trust … 0.03% 3353 SH 1 अक्टूबर 2026 दैनिक
VONV · VANGUARD SCOTTSDALE FUNDS 0.03% 67429 SH 19 अगस्त 2026 दैनिक
TOPC · iShares Trust 0.03% 72 SH 11 सितमबर 2026 दैनिक
PBP · Invesco Exchange-Traded Fund Trust 0.03% 660 SH 1 अक्टूबर 2026 दैनिक
TILT · FlexShares Trust 0.02% 4536 NS 31 जुलाई 2026 N-PORT
XVV · iShares Trust 0.02% 1280 SH 11 सितमबर 2026 दैनिक
DFAU · Dimensional ETF Trust 0.02% 24920 NS 31 जुलाई 2026 N-PORT
PHDG · Invesco Actively Managed Exchange-T… 0.02% 89 SH 30 सितमबर 2026 दैनिक
XYLG · Global X Funds 0.02% 120 NS 31 जुलाई 2026 N-PORT
IVV · iShares Trust 0.02% 1406050 SH 11 सितमबर 2026 दैनिक
XYLD · Global X Funds 0.02% 5804 NS 31 जुलाई 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0.02% 2897314 SH 19 अगस्त 2026 दैनिक
VTI · VANGUARD INDEX FUNDS 0.02% 3545801 SH 19 अगस्त 2026 दैनिक
VONE · VANGUARD SCOTTSDALE FUNDS 0.02% 18403 SH 19 अगस्त 2026 दैनिक
VTHR · VANGUARD SCOTTSDALE FUNDS 0.02% 9418 SH 19 अगस्त 2026 दैनिक
ESGV · VANGUARD WORLD FUND 0.02% 25220 SH 19 अगस्त 2026 दैनिक
IYY · iShares Trust 0.02% 4913 SH 11 सितमबर 2026 दैनिक
PTLC · Pacer Funds Trust 0.02% 5733 NS 31 जुलाई 2026 N-PORT
IWB · iShares Trust 0.02% 77050 SH 11 सितमबर 2026 दैनिक
XCLR · Global X Funds 0.02% 6 NS 31 जुलाई 2026 N-PORT
ITOT · iShares Trust 0.02% 147486 SH 11 सितमबर 2026 दैनिक
RWL · Invesco Exchange-Traded Fund Trust … 0.02% 11723 SH 1 अक्टूबर 2026 दैनिक
IWV · iShares Trust 0.02% 30674 SH 11 सितमबर 2026 दैनिक
DFUS · Dimensional ETF Trust 0.02% 33978 NS 31 जुलाई 2026 N-PORT
XRMI · Global X Funds 0.02% 81 NS 31 जुलाई 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0.02% 421 NS 31 जुलाई 2026 N-PORT
QDPL · Pacer Funds Trust 0.02% 2684 NS 31 जुलाई 2026 N-PORT
XTR · Global X Funds 0.02% 7 NS 31 जुलाई 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0.02% 779 NS 31 जुलाई 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0.01% 8723 NS 31 जुलाई 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0.01% 3445 SH 1 अक्टूबर 2026 दैनिक
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.01% 98929 SH 19 अगस्त 2026 दैनिक
BIV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BLV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BSV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BND · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
VCSH · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VCIT · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VCLT · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VTC · VANGUARD SCOTTSDALE FUNDS · · 30 जुलाई 2026 दैनिक
BNDW · VANGUARD SCOTTSDALE FUNDS · · 14 जुलाई 2026 दैनिक
ISCB · iShares Trust · 5032 SH 11 सितमबर 2026 दैनिक
ISCV · iShares Trust · 15028 SH 11 सितमबर 2026 दैनिक

RVTY विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

21
रेटिंग · 25 विश्लेषक खरीदें
मध्यिका लक्ष्य $125.50 -17.2%
5 20.0% मजबूत खरीद
8 32.0% खरीदें
12 48.0% होल्ड
0 0.0% बेचें
0 0.0% मजबूत बिक्री

12-महीने का मूल्य लक्ष्य

16 विश्लेषक · 2026-09-28

माध्य लक्ष्य $129.00 -14.9%

अभी वर्तमान मूल्य $151.53
निम्न$110.00 माध्य$129.00 उच्च$165.00

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

22

वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
RVTY $10.86B 46.7 3.7% 8.5% 3.3% ·
WAT $22.62B 35.3 7.0% 20.3% 27.2% ·
IQV $38.23B 28.8 5.9% 8.3% 21.6% ·
ILMN $20.65B 24.8 -0.66% 19.6% 34.1% 66.1%
MTD $28.38B 33.2 4.0% 21.6% -615.5% 59.4%
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
CRL $10.02B -70.0 -0.85% -3.6% -4.4% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TXG $2.08B -46.6 5.2% -6.8% -5.5% 69.0%

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

26

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

स्रोत: SEC 10-Q अग 11, 2026 को फाइल किया गया